Clinical response to sodium glucose co‐transporter 2 inhibitor ipragliflozin in a patient with metastatic renal cell carcinoma

• Main Authors: Keita Izumi, Yasumasa Iimura, Kiyoshi Hiruma, Tsuguhiro Touma, Tetsuro Tsukamoto
• Format: Article
• Language: English
• Published: Wiley 2019-09-01
• Series: IJU Case Reports
• Subjects: diabetes mellitus; renal cell carcinoma; sodium glucose transporter 2 inhibitor
• Online Access: https://doi.org/10.1002/iju5.12099

Introduction Sodium glucose co‐transporter 2 inhibitors constitute a new class of antidiabetic medication. Sodium glucose co‐transporter 2 inhibitors have been shown to exert anticancer effects. However, the clinical value of these drugs as anticancer agents is yet to be evaluated. Case presentation A 72‐year‐old man presented to our hospital with frequent cough and dyspnea. Contrast‐enhanced computed tomography revealed renal cell carcinoma cT3bN0M1. Ipragliflozin, a sodium glucose co‐transporter 2 inhibitor, treatment was initiated to control blood glucose levels. Two years after diagnosis, computed tomography revealed remarkable tumor regression without any systemic therapy other than ipragliflozin. Conclusion Sodium glucose co‐transporter 2 inhibitors are potentially applicable as anticancer agents among patients with metastatic renal cell carcinoma.